From: Image guided dose escalated prostate radiotherapy: still room to improve
Risk Factor | Number | Nadir +2 5-year bNED | p-value | HR (95%CI) |
---|---|---|---|---|
PSA | Â | Â | Â | Â |
   <10 | 180 | 74.4% |  |  |
   10-20 | 63 | 79.4% |  |  |
   >20 | 16 | 75% |  |  |
Continuous variable | Â | Â | 0.85 | 1.00 (0.96-1.03) |
Gleason grade | Â | Â | Â | Â |
   5-6 | 96 | 82.3% | 0.15 | (reference) |
   7 | 141 | 71.6% | 0.06 | 1.73 (0.98-3.05) |
   8-10 | 21 | 71.4% | 0.21 | 1.81 (0.71-4.59) |
T-category | Â | Â | Â | Â |
   T1b-T2a | 209 | 83.0% | 0.006 | (reference) |
   T2b-T2c | 43 | 64.9% | 0.002 | 2.48 (1.42-4.36) |
   T3a-TX | 7 | 68.6% | 0.56 | 1.56 (0.37-6.30) |
Risk Grouping | Â | Â | Â | Â |
   Low | 59 | 86.4% | 0.14 | 1 (reference) |
   Intermediate | 163 | 73% | 0.06 | 2.04 (0.96-4.34) |
   High | 37 | 70.3% | 0.07 | 2.33 (0.94-5.78) |
Adjuvant Hormone | Â | Â | Â | Â |
   No | 165 | 76.4% | 0.52 | 1 (reference) |
   Yes | 31 | 72.1% | 0.66 | 0.81 (0.43-1.53) |
Age | Â | Â | Â | Â |
Continuous variable | Â | Â | 0.66 | 1.01(0.97-1.05) |